Pfizer Inc announced that, in patients with heart disease, type 2 diabetes and chronic kidney disease, LipitorĀ® (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 35 percent compared with Lipitor 10 mg. This finding is from a subanalysis designed and completed following the closure of the five-year Treating to New Targets (TNT) study in patients with existing coronary heart disease.
Go to Source
You can skip to the end and leave a response. Pinging is currently not allowed.
Be nice. Keep it clean. Stay on topic. No spam.
You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>